BIAFWbioAffinity Technologies Inc. Warrant
0.1165USD+11.70%Mkt Cap: —P/E: —3d ago
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United Sta…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)5.90M $
Gross Profit1.88M $
Net Income (TTM)-14.91M $
Revenue/Share1.547 USD
Last Price0.1165 USD
Fiscal Year End—
MR Quarter—
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.19
EPS (TTM)—
EPS (Forward)—
52W Range
0.050127% of range0.2950
52W High0.2950 USD
52W Low0.0501 USD
Profitability
Gross Margin30.80%
Oper. Margin-220.77%
EBITDA Margin-202.82%
Profit Margin-244.10%
ROE-204.87%
ROA-136.03%
Growth
Revenue Growth19.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.33M $
CapEx (TTM)60.57K $
FCF Margin-117.09%
FCF Yield—
Net Debt-994.71K $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.16
Current Ratio1.44
Quick Ratio1.24
Book Value/Sh0.5560 USD
Cash/Share0.3000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.98M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-1.05
S&P 52W Chg18.16%
Avg Vol (30d)1.44K
Avg Vol (10d)—
Technical Indicators
RSI (14)46.9
MACD-0.0370
MACD Signal-0.0419
MACD Hist.+0.0049
BB Upper0.2772 USD
BB Middle0.1260 USD
BB Lower-0.0251 USD
BB Width239.90%
ATR (14)0.0466 USD
Vol Ratio (20d)2.61x